The BTK inhibitors market is poised for remarkable growth driven by advancements in oncology and autoimmune disease treatments. With expanding research and development efforts, these inhibitors ...

Drug repurposing benefits from existing compounds with optimized structures and approved for clinical use with associated structure-activity relationship ... the Bruton Tyrosine Kinase (BTK) inhibitor ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo(axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...

Meaghan Senn is a writer from North Carolina with experience in B2B, technology and digital marketing topics. Throughout her career, Meaghan has worked with B2B, software and digital marketing ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Treatment is usually initiated in patients with active symptomatic disease (Mukkamalla et al, 2023), and includes ibrutinib, acalabrutunib, and zanubrutinib. These inhibit B cell proliferation and, in ...

Minimum investments vary for each fund, the structure of private equity funds historically follows a framework that includes classes of fund partners, management fees, investment horizons ...

Figure 1. Structure of the focal adhesion kinase (FAK) protein. The structure of FAK is shown with the three main domains. The phosphorylation sites (P) and proline-rich regions (PRRs) are shown. The ...

A model showing how metallic bonds are formed - the first diagram shows the outer electrons in their atoms, and the second diagram shows that the electrons have become delocalised ...